European journal of haematology · 2026
Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Milojkovic Dragana, Cross Nicholas C P, Desai Ketul, Frewin Kathryn, Copland Mhairi
Аннотация
OBJECTIVE: Chronic myeloid leukaemia in chronic phase (CML-CP) treatment recommendations have changed substantially in recent years. The ADAPT 2.0 survey aimed to provide an updated understanding of CML-CP management in the UK.
METHODS: This healthcare professional (HCP) survey, conducted between December 2023 and June 2024, assessed treatment goals, choice of tyrosine kinase inhibitors (TKIs), unmet needs and approaches to treatment-free remission (TFR).
RESULTS: UK CML-CP practise is generally aligned with the contemporary guidelines for CML management. Key treatment goals were major molecular response (54%-77% across treatment lines) and deep molecular response (5%-46%). The main factors influencing first-line (1 L) TKI selection were treatment guidelines (97%), comorbidities (90%) and TFR as a treatment goal (82%). Therapy switch after one warning European LeukemiaNet (ELN) 2020 response was rare (10% vs. 56% in patients with > 1 warning response and 100% in failure response). BCR::ABL1 mutation analysis was less common after one warning response versus > 1 warning response (54% vs. 82%). TKI toxicity, resistance, intolerance and T315I mutation management were key unmet needs in later treatment lines; achieving and maintaining TFR were key unmet needs in 1 L.
CONCLUSION: The ADAPT 2.0 survey highlights potential areas of improvement in current CML-CP management in the UK.
METHODS: This healthcare professional (HCP) survey, conducted between December 2023 and June 2024, assessed treatment goals, choice of tyrosine kinase inhibitors (TKIs), unmet needs and approaches to treatment-free remission (TFR).
RESULTS: UK CML-CP practise is generally aligned with the contemporary guidelines for CML management. Key treatment goals were major molecular response (54%-77% across treatment lines) and deep molecular response (5%-46%). The main factors influencing first-line (1 L) TKI selection were treatment guidelines (97%), comorbidities (90%) and TFR as a treatment goal (82%). Therapy switch after one warning European LeukemiaNet (ELN) 2020 response was rare (10% vs. 56% in patients with > 1 warning response and 100% in failure response). BCR::ABL1 mutation analysis was less common after one warning response versus > 1 warning response (54% vs. 82%). TKI toxicity, resistance, intolerance and T315I mutation management were key unmet needs in later treatment lines; achieving and maintaining TFR were key unmet needs in 1 L.
CONCLUSION: The ADAPT 2.0 survey highlights potential areas of improvement in current CML-CP management in the UK.